The power of multidisciplinary working – Myeloma UK at IMS 2024

Held in Rio de Janeiro, the 21st International Myeloma Society (IMS) Meeting and Exposition, in combination with the 8th Nursing and Allied Health Symposium brought together myeloma specialists from around the globe. The events spanned 25–28th September 2024 and Myeloma UK’s attendance ensured our contributions to myeloma patient care were shared on the international stage

Details

New good practice paper offers much-needed guidance for diagnosis and treatment of high-risk myeloma patients

In June, the British Society for Haematology (BSH) and the UK Myeloma Society (UKMS) published a comprehensive good practice paper outlining recommendations for the diagnosis and initial treatment of transplant-eligible high-risk myeloma patients. Here we discuss this major step towards realising suitable provision for this unmet patient need.

Details

Beyond the clinic: Healthcare professionals pedal for progress

We caught up with Myeloma Clinical Nurse Specialist (CNS) Sue Robb, and Consultant Haematologist and Myeloma UK Chief Clinical and Scientific Officer, Professor Graham Jackson, just before they headed off to the Myeloma UK London Paris Ride start line. In this Q&A, they tell us about their motivations for supporting Myeloma UK and how, collectively, we create change together.

Details

Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: BSH Good Practice Paper

The British Society for Haematology (BSH) and the UK Myeloma Society have published a comprehensive Good Practice Paper on the diagnosis and initial treatment of transplant-eligible high-risk myeloma patients. Authored by leading experts in the field, this paper provides crucial recommendations based on the latest genetic diagnostics and prospective clinical trial evidence for high-risk myeloma.…

Details